Similar articles

Abstract: This study aimed to assess the inhibitory activities of methanol extracts from the microalgae Ankistrodesmus convolutus, Synechococcus elongatus, and Spirulina platensis against epstein-Barr virus (EBV) in three Burkitt’s lymphoma (BL) cell lines, namely Akata, B95-8, and P3HR-1. The antiviral activity was assessed by quantifying the cell-free EBV DNA using real-time polymerase chain reaction (PCR) technique. The methanol extracts from Ankistrodesmus convolutus and Synechococcus elongatus displayed low cytotoxicity and potent effect in reducing cell-free EBV DNA (EC₅₀<0.01 µg/ml) with a high therapeutic index (>28000). After fractionation by column chromatography, the fraction from Synechococcus elongatus (SEF1) reduced the cell-free EBV DNA most effectively (EC₅₀=2.9 µg/ml, therapeutic index>69). Upon further fractionation by high performance liquid chromatography (HPLC), the sub-fraction SEF1’a was most active in reducing the cell-free EBV DNA (EC₅₀=1.38 µg/ml, therapeutic index>14.5). This study suggests that microalgae could be a potential source of antiviral compounds that can be used against EBV.

[1]Adamson, A.L., Darr, D., Holley-Guthrie, E., Johnson, R.A., Mauser, A., Swenson, J., Kenney, S., 2000. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol., 74(3):1224-1233.

[2]Akihisa, T., Taguchi, Y., Yasukawa, K., Tokuda, H., Akazawa, H., Suzuki, T., Kimura, Y., 2006. Acerogenin M, a cyclic diarylheptanoid, and other phenolic compounds from Acer nikoense and their anti-inflammatory and anti-tumor-promoting effects. Chem. Pharm. Bull., 54(5):735-739.

[3]Ballout, M., Germi, R., Fafi-Kremer, S., Guimet, J., Bargues, G., Seigneurin, J., Morand, P., 2007. Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression. J. Virol. Methods, 143(1):38-44.

[4]Buck, C.B., Thompson, C.D., Roberts, J.N., Müller, M., Lowy, D.R., Schiller, J.T., 2006. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathogens, 2(7):e69.

[5]Chang, Y., Tung, C.H., Huang, Y.T., Lu, J., Chen, J.Y., Tsai, C.H., 1999. Requirement of cell to cell contact in EBV infection of NPC and keratinocytes. J. Virol., 73(10):8857-8866.

[6]Chêne, A., Donati, D., Guerreriro-Cacais, A.O., Levitsky, V., Chen, Q., Falk, K.I., Orem, J., Kironde, F., Wahlgren, M., Bejarano, M.T., 2007. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathogens, 3(6):e80.

[7]Chu, W.L., Phang, S.M., Goh, S.H., 1995. Influence of carbon source on the growth, biochemical composition and pigmentation of Ankistrodesmus convolutus. J. Appl. Phycol., 7(1):59-64.

[8]Daibata, M., Bandobashi, K., Kuroda, M., Imai, S., Miyoshi, I., Taguchi, H., 2005. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. J. Virol., 79(9):5875-5879.

[9]Fang, C.Y., Lee, C.H., Wu, C.C., Chang, Y.T., Yu, S.L., Chou, S.P., Huang, P.T., Chen, C.L., Hou, J.W., Chang, Y., et al., 2009. Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int. J. Cancer, 124(9):2016-2025.

[10]Feng, P., Ren, E.C., Liu, D., Chan, S.H., Hu, H., 2000. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis. J. Gen. Virol., 81(Pt 10):2417-2423.

[11]Gershburg, E., Pagano, J.S., 2005. Epstein-Barr virus infections: prospects for treatment. J. Antimicrob. Chemother., 56(2):277-281.

[12]Hemmingson, J.A., Falshaw, R., Furneaux, R.H., Thompson, K., 2006. Structure and antiviral activity of the galactofucan sulfates extracted from Undaria pinnatifida (Phaeophyta). J. Appl. Phycol., 18(2):185-193.

[13]Huleihel, M., Ishanu, V., Tal, J., Arad, S., 2001. Antiviral effect of red microalgal polysaccharides on Herpes simplex and Varicella zoster viruses. J. Appl. Phycol., 13(2):127-134.

[14]Klein, G., 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell, 77(6):791-793.

[15]Krenauer, A., Moll, A., Ponisch, W., Schmitz, N., Niedobitek, G., Niederwieser, D., Aigner, T., 2010. EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression—a case report. Diagn. Pathol., 5(1):21.

[16]Kurth, J., Spieker, T., Wustrow, J., Strickler, G.J., Hansmann, L.M., Rajewsky, K., Küppers, R., 2000. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity, 13(4):485-495.

[17]Lai, P.J., Chu, W.L., Naidu, R., Khoo, A.S.B., Kok, Y.Y., Shar, M.M., Ling, S.N., Mak, J.W., Lim, K.C., Balraj, P., et al., 2008. Antiproliferative activity of microalgal extracts on nasopharyngeal carcinoma (NPC) cells. Malaysian J. Sci., 27(2):19-31.

[18]Lin, J.C., 2003. Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro. Antiviral Res., 59(1):41-47.

[19]Lin, T.P., Chen, S.Y., Duh, P.D., Chang, L.K., Liu, Y.N., 2008. Inhibition of the Epstein-Barr virus lytic cycle by andrographolide. Biol. Pharm. Bull., 31(11):2018-2023.

[20]Lo, D.Y.M., Chan, L.Y.S., Lo, K.W., Leung, S.F., Zhang, J., Chan, A.T.C., Lee, J.C.K., Hjelm, N.M., Johnson, P.J., Huang, D.P., 1999. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res., 59:1188-1191.

[21]Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65(1-2):55-63.

[22]Ohigashi, H., Sakai, Y., Yamaguchi, K., Umezaki, I., Koshimizu, K., 1992. Possible anti-tumor promoting properties of marine algae and in vivo activity of Wakame seaweed extract. Biosci. Biotechnol. Biochem., 56(6):994-995.

[23]Phang, S.M., Chu, W.L., 1999. University of Malaya Algae Culture Collection (UMACC): Catalogue of Strains. Institute of Postgraduate Studies and Research, University of Malaya, Kuala Lumpur, Malaysia, p.77.

[24]Rechter, S., König, T., Auerochs, S., Thulke, S., Walter, H., Dörnenburg, H., Walter, C., Marschall, M., 2006. Antiviral activity of Arthrospira-derived spirulan-like substances. Antiviral Res., 72(3):197-206.

[25]Rezk, S., Weiss, L., 2007. Epstein-Barr virus-associated lymphoproliferative disorders. Human Pathol., 38(9):1293-1304.

[26]Rickinson, A.B., Kieff, E., 1996. Epstein-Barr Virus. In: Fields, B.N., Knipe, B.N., Howley, P.M. (Eds.), Fields Virology. Lippincott-Williams and Wilkins, Philadelphia, p.2397-2476.

[27]Rocha, F.D., Soares, A.R., Houghton, P.J., Pereira, R.C., Kaplan, M.A.C., Teixeira, V.L., 2007. Potential cytotoxic activity of some Brazilian seaweeds on human melanoma cells. Phytother. Res., 21(2):170-175.

[28]Schwarzmann, F., Jager, M., Horner, M., Prang, N., Wolf, H., 1998. Epstein-Barr viral gene expression in B-lymphocytes. Leuk. Lymphoma, 30(1-2):123-129.

[29]Takada, K., Shimizu, N., Tanabe-Tochikura, A., Kuroiwa, Y., 1995. Pathogenic role of Epstein-Barr virus in human cancer. Intervirology, 38(3-4):214-220.

[30]Walling, D.M., Flaitz, C.M., Nicholas, C.M., 2003. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J. Infect. Dis., 188(6):883-890.